Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
The current study provides a valuable evaluation of the postmarketing safety of belimumab. Further studies are required to validate and confirm these findings. Clinicians should be vigilant regarding these potential AEs and pay more attention to the proper dosage regimen of belimumab in clinical practice.
Authors
- Chongshu Wang
- Wen-Long Xie
- Huqun Li
- Cuilian Guo
Institutions
- Central Hospital of Wuhan (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/lupus-2024-001400
- Citations
- 3
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 4.18